Literature DB >> 11750930

Drug delivery to damaged brain.

E H Lo1, A B Singhal, V P Torchilin, N J Abbott.   

Abstract

Drug delivery to the brain poses unique challenges. Specialized anatomic and physiological features of the cerebrovasculature and cerebral tissue fluids result in barriers which significantly restrict delivery of a wide range of possible therapeutic agents. In addition to these normal restrictions to brain drug delivery, pathophysiological features and sequelae of acute brain injury will also impact upon the efficiency of drug delivery. This review is focused on acutely damaged brain that occurs after stroke and trauma. Pathophysiological events that may influence drug delivery include blood-brain barrier disruptions, blood flow alterations, edema and increased intracranial pressure, metabolic perturbations, and altered profiles of gene expression and protein synthesis. Careful consideration of these obstacles will provide a framework for further research into the optimization of drug delivery strategies into damaged brain. Without a rigorous assessment of these issues, it may not be possible to translate our mechanistic understanding of acute brain injury into successful clinical therapies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11750930     DOI: 10.1016/s0165-0173(01)00083-2

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  36 in total

Review 1.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 2.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

Review 3.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Film interface for drug testing for delivery to cells in culture and in the brain.

Authors:  Min D Tang-Schomer; David L Kaplan; Michael J Whalen
Journal:  Acta Biomater       Date:  2019-03-02       Impact factor: 8.947

Review 5.  Neuro-oxidative-nitrosative stress in sepsis.

Authors:  Ronan M G Berg; Kirsten Møller; Damian M Bailey
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-13       Impact factor: 6.200

Review 6.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 7.  Magnetic nanoparticle-based approaches to locally target therapy and enhance tissue regeneration in vivo.

Authors:  Richard Sensenig; Yulia Sapir; Cristin MacDonald; Smadar Cohen; Boris Polyak
Journal:  Nanomedicine (Lond)       Date:  2012-09       Impact factor: 5.307

Review 8.  Nanotechnology: toxicologic pathology.

Authors:  Ann F Hubbs; Linda M Sargent; Dale W Porter; Tina M Sager; Bean T Chen; David G Frazer; Vincent Castranova; Krishnan Sriram; Timothy R Nurkiewicz; Steven H Reynolds; Lori A Battelli; Diane Schwegler-Berry; Walter McKinney; Kara L Fluharty; Robert R Mercer
Journal:  Toxicol Pathol       Date:  2013-02-06       Impact factor: 1.902

Review 9.  Novel technologies for antiangiogenic drug delivery in the brain.

Authors:  Ofra Benny; Pouya Pakneshan
Journal:  Cell Adh Migr       Date:  2009-04-06       Impact factor: 3.405

10.  Solid lipid nanoparticles as delivery systems for bromocriptine.

Authors:  Elisabetta Esposito; Martina Fantin; Matteo Marti; Markus Drechsler; Lydia Paccamiccio; Paolo Mariani; Elisa Sivieri; Francesco Lain; Enea Menegatti; Michele Morari; Rita Cortesi
Journal:  Pharm Res       Date:  2008-01-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.